In the same 2025 study by Qeadan and colleagues, individuals with a history of opioid use disorder (n=503,747) prescribed GLP-1 medications had about a 40% lower rate of opioid overdose events during the 2-year follow-up period (Qeadan et al., 2025)
Aunque el mecanismo exacto an no est claro, los autores destacan que el beneficio podra estar mediado por la disminucin de la inflamacin sistmica y la mejora metablica
According to the authors, this study provides evidence that GLP-1 RAs are associated with thyroid cancer in patients with diabetes [58]
If your insurer denies coverage, you have the right to appeal
Pharma is innovating to hit even more targets The latest article I saw about the work being done in this class is a study in mice looking at a quintuple agonist (5 different targets!) I almost never write about mice studies because of how preliminary they are and how unlikely a finding in mice is to ever translate into anything useful in humans, but because of the success weve already seen of this drug class as well as the way that hitting more pathways seems to increase efficacy, I thought this was research worth highlighting
